OxiGene starts Phase II colorectal cancer trial

OXGN began a U.S. Phase II trial of its Declopramide (Oxi-104) oral third generation N-substituted benzamide compound that inhibits NF-kB and induces apoptosis, in combination with intravenous 5-fluor...